Volution Immunotherapeutics Q2 revenue down 84% YoY to $201,444.

sábado, 10 de enero de 2026, 11:09 am ET1 min de lectura
AKTX--

• Volition Immunotherapeutics reports Q2 2015 financial results. • Cash and cash equivalents at $201,444, up from $3,135 in December 2014. • No specific data on digital data provided in the article.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios